Blood Advances · 2023 · 27 citations · 33 references
Life SciencesImmunologyOncologyCell TherapyClinical ImmunologyImmunotherapyB Cell BiologyCancer ImmunotherapyChimeric Antigen Receptor T-cell TherapyMultiple MyelomaAllogeneic Car T-cell TherapyAllogeneic Immune Cell TherapyAutologous Car T-cell TherapyChimeric Antigen Receptor T-cell Therapy ToxicityCytokine Mediator ReleaseImmune Effector Cell FunctionImmune Effector FunctionsImmune Effector Molecules
Multiple myeloma (MM), a malignancy of mature plasma cells, remains incurable. B-cell maturation antigen (BCMA) is the lead protein target for chimeric antigen receptor (CAR) therapy because of its high expression in most MM, with limited expression in other cell types, resulting in favorable on-target, off tumor toxicity. The response rate to autologous BCMA CAR-T therapy is high; however, it is not curative and is associated with risks of cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome. Outcomes in patients treated with BCMA CAR-T cells (CAR-Ts) may improve with allogeneic CAR T-cell therapy, which offer higher cell fitness and reduced time to treatment. However, to prevent the risk of graft-versus-host disease (GVHD), allogenic BCMA CAR-Ts require genetic deletion of the T-cell receptor (TCR), which has potential for unexpected functional or phenotype changes. Invariant natural killer T cells (iNKTs) have an invariant TCR that does not cause GVHD and, as a result, can be used in an allogeneic setting without the need for TCR gene editing. We demonstrate significant anti-myeloma activity of BCMA CAR-iNKTs in a xenograft mouse model of myeloma. We found that a long-acting interleukin-7 (IL-7), rhIL-7-hyFc, significantly prolonged survival and reduced tumor burden in BCMA CAR-iNKT-treated mice in both primary and re-challenge settings. Furthermore, in CRS in vitro assays, CAR-iNKTs induced less IL-6 than CAR-Ts, suggesting a reduced likelihood of CAR-iNKT therapy to induce CRS in patients. These data suggest that BCMA CAR-iNKTs are potentially a safer, effective alternative to BCMA CAR-Ts and that BCMA CAR-iNKT efficacy is further potentiated with rhIL-7-hyFc.
33
Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma
Nikhil C. Munshi, Larry D. Anderson, Nina Shah et al. · New England Journal of Medicine · 2021 · 2.4K citations · Full text
Medicine, Hematology, Oncology +17
Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors
Enli Liu, David Marín, Pinaki P. Banerjee et al. · New England Journal of Medicine · 2020 · 2.1K citations · Full text
Life Sciences, Immunology, Oncology +17
Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma
Noopur Raje, Jesús G. Berdeja, Yi Lin et al. · New England Journal of Medicine · 2019 · 1.7K citations · Full text
Medicine, Immunology, Oncology +17
Jennifer N. Brudno, Irina Marić, Steven D. Hartman et al. · Journal of Clinical Oncology · 2018 · 791 citations · Full text
Medicine, Hematology, Immunology +15